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Abstract
Background: A-kinase-anchoring proteins, AKAPs, constitute a family of scaffolds that play an essential role in
catalyzing the spatial-temporal, dynamic interactions of protein kinase A, protein kinase C, tyrosine kinases, G-
protein-coupled receptors and ion channels. We studied AKAP5 (AKAP79; MW ~47 kDa) and AKAP12 (gravin,
SSECKS; MW ~191 kDa) to probe if these AKAP scaffolds oligomerize.
Results: In gel analysis and sodium-dodecyl sulfate denaturation, AKAP12 behaved with a MW of a homo-dimer.
Only in the presence of the chaotropic agent 8 M urea did gel analysis reveal a monomeric form of AKAP12. By
separation by steric-exclusion chromatography, AKAP12 migrates with MW of ~840 kDa, suggestive of higher-order
complexes such as a tetramer. Interestingly, the N-(1-840) and C-(840-1782) terminal regions of AKAP12 themselves
retained the ability to form dimers, suggesting that the structural basis for the dimerization is not restricted to a
single “domain” found within the molecule. In either sodium dodecyl sulfate or urea, AKAP5 displayed a relative
mobility of a monomer, but by co-immunoprecipitation in native state was shown to oligomerize. When subjected
to steric-exclusion chromatography, AKAP5 forms higher-order complexes with MW ~220 kDa, suggestive of
tetrameric assemblies.
Conclusion: Both AKAP5 and AKAP12 display the capacity to form supermolecular homo-oligomeric structures that
likely influence the localization and function of these molecular scaffolds.
Background
Discovery of a docking site for the regulatory subunits
(i.e., RI/RII) of cyclic AMP-dependent protein kinase A
(PKA, A-kinase) was seminal in our understanding of
the roles of A-kinase-anchoring protein (AKAP) scaf-
folds in cellular signaling [1-4]. AKAPs not only dock
PKA, but act as molecular “tool boxes” that are multiva-
lent and capable of docking other protein kinases (pro-
tein kinase C and the tyrosine kinase Src),
phosphoprotein phosphatases, such as protein phospha-
tase 2B (PP2B) [5], cyclic AMP phosphodiesterases
(PDE) [6-9], adaptor molecules [8-11], ion channels
[12-14], and members of the superfamily of G protein-
coupled receptors (GPCR) [15-17]. Two AKAPs, AKAP5
and AKAP12, that associate with the prototypic GPCR,
the b2-adrenergic receptor (b2-AR), have been the focus
of intense research [16,18-21]. Herein, we examine these
two members of the class of GPCR-associated AKAPs
and explore the extent to which these proteins, whose
structure is predicted to be natively unordered [5], are
capable of forming oligomers. The current work is the
f i r s tt or e p o r tt h a tb o t hA K A P 5a n dA K A P 1 2a r en o t
only capable of forming homodimers, but also of form-
ing higher-order supermolecular homo-oligomeric com-
plexes. Thus AKAP oligomerization adds a new
dimension on how members of this class of scaffold
molecules operate in cell signaling.
Results
Oligomerization of AKAP12
W ef i r s ts o u g h tt oi n t e r r o g a te if oligomerization of
AKAP12 could be detected using purified human
AKAP12. Consequently, His-tagged human AKAP12
was expressed in E. coli, purified by gel filtration chro-
matography, and analyzed by SDS-PAGE. Analysis of
the expressed, purified AKAP12 in the presence of the
denaturant SDS revealed a Mr of ~500 kDa, slightly
more than twice the mass of that calculated (hAKAP12,
MW = 191.5 kDa) based upon primary sequence alone
(see protein staining, Figure 1A). The nature of the 500
kDa-Mr species was made clear by performing the same
analysis, but with prior sample treatment and SDS-
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Figure 1 Oligomerization of AKAP12 (and either C-terminal or N-terminal fragments) expressed and purified from E. coli. His-tagged
AKAP12 or His-tagged AKAP12 fragments were expressed in E. coli. The AKAP12 (or fragments) were purified and then resolved on SDS-PAGE in
the absence (A) or presence of 8 M urea (B). The gels were fixed and stained for protein with Coomassie Brilliant Blue (A, B) or the resolved
proteins transferred to PVDF membrane and subjected to immunoblotting (C, D). The “◀” indicates the observed Mr on the gels and the “Δ”
indicates the predicted Mr, calculated from the primary sequence.
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Page 2 of 12PAGE separation performed in the presence of the
chaotropic agent 8 M urea (Figure 1B). In the presence
of 8 M urea, the apparent Mr of purified AKAP12
declined from ~500 kDa to ~250 kDa, emblematic of a
monomeric form of this large AKAP. The results
obtained of fixed gels, stained for protein (Figure 1A, B)
were further tested using immunoblotting to detect the
protein (Figure 1C, D). Immunoblots of the resolved,
transferred protein that were stained with antibodies to
the His-tag confirmed the results of the protein staining
(Figures 1C, D). AKAP12 forms oligomers that are SDS-
resistant. Homodimeric AKAP12 can only be disas-
sembled by treatment and separation in 8 M urea, a
strong chaotropic agent.
S i n c ew ee s t a b l i s h e dt h ee x i s t e n c eo fA K A P 1 2o l i g o -
mers using SDS-PAGE, we probed the upper limit size
of AKAP12 oligomers. AKAP12 purified from E. coli
was subjected to steric-exclusion chromatography on a
high-resolution, wide-bore matrix operated by an
AKTA FPLC system (Figure 2). A spark symmetrical
peak of protein (A280) and of AKAP12 immunoreac-
tivity (see blot inset) was resolved. Using a set of mar-
ker proteins of known Mr,w ew e r ea b l et os i z et h e
AKAP12 supermolecular complexes with precision.
The Mr of the AKAP12 was 830-850 kDa. AKAP12
appears to form oligomers greater than dimers, mini-
mally trimeric or even tetrameric. This higher order
assembly of AKAPs into supermolecular complexes is
a novel observation.
We probed the same queries for AKAP12 expressed in
mammalian cells. Human embryonic kidney 293
(HEK293) cells transfected with an expression vector
harboring the human AKAP12 were collected, lysed,
and the mobility of AKAP12 established by SDS-PAGE
(Figure 3A). Homodimers of HA-tagged AKAP12 exo-
genously expressed in HEK293 cells were found to be
resistant to SDS denaturation. By SDS-PAGE analysis, a
~500 kDa-Mr immunoreactive band was obvious,
whether the immunoblots were stained with anti-
AKAP12 or anti-HA antibodies (Figure 3A). When the
samples were treated with and subjected to SDS-PAGE
in the presence of 8 M urea, the Mr of the immunoreac-
tive band of AKAP12 declined from ~500 kDa to ~250
kDa (Figure 3B). This ~250 kDa mobility is consistent
with the MW calculated for the monomeric form of the
scaffold protein from primary sequence.
We investigated if N-terminal (1-840) and C-terminal
(840-1782) fragments of AKAP12 would retain the abil-
ity to form dimers, as observed with the full-length
AKAP12 (Figure 1A, B). Expression vectors harboring
either the His-tagged N-terminal or the C-terminal
region of AKAP12 were constructed, the protein was
expressed in E. coli, and each of the two large fragments
was purified by affinity chromatography. Protein staining
of the N- and C-terminal fragments resolved by gel ana-
lysis in the presence of SDS reveals, remarkably, the
homodimerization of both the N-terminal as well as the
C-terminal fragments of AKAP12 (Figure 1A). In the
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Figure 2 Steric-exclusion chromatography of purified AKAP12. His-tagged AKAP12 was purified and then resolved by steric-exclusion
chromatography performed on an AKTA FPLC fitted with HiPrep Sephacryl-S400 (16/60) column. The presence of supermolecular oligomers of
AKAP12 was established by SDS-PAGE and immunoblotting of samples from the chromatography. The resolved, transferred proteins were
stained with anti-AKAP12 antibodies. Marker protein mobilities were employed to establish the Mr of AKAP12 by elution position (inset). The
results displayed are representative of three separate experiments performed on as many separate cell cultures.
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Page 3 of 12presence of 8 M urea, however, the N-terminal and C-
terminal fragments of AKAP12 now can be resolved as
monomeric forms (Figure 1B). Immunoblotting of the
His-tagged fragments resolved in SDS (Figure 1C, D)
confirms the identity of the species made visible by pro-
tein staining (Figure 1A, B), i.e., both AKAP12 frag-
ments behave as dimers in SDS-PAGE. In the presence
of 8 M urea, the N- and C-terminal fragments made
visible by protein staining (Figure 1B) likewise resolve as
the monomeric forms, as made visible by immunoblot-
ting (Figure 1C, D).
The electrophoretic behavior of full-length human
AKAP12, as well as the N- and the C-fragments was
probed when these fragments were expressed in mam-
malian (HEK293) cells, rather than in E. coli.T h e
expressed HA-tagged versions of the full-length
AKAP12 (1-1782), the N-terminal fragment (1-938), and
a C-terminal (840-1782) fragment of AKAP12 were sub-
jected to SDS-PAGE, immunoblotting of the resolved
proteins, and made visible by staining with anti-HA
antibody (Figure 3A, B). In the presence of SDS, HA-
tagged AKAP12 displays a Mr of a dimer (Figure 3A).
Immunostaining of the HEK cell extracts with anti-
AKAP12 antibody likewise displays the same homodi-
meric character. When treated and resolved on gels in
the presence of 8 M urea, either exogenously (probed
with anti-HA immunostaining) or endogenously (probed
with anti-AKAP12 antibody) expressed AKAP12
migrated with a Mr of a monomer (Figure 3B). Both the
N-terminal as well as the C-terminal fragments of
AKAP12 expressed in mammalian cells displayed dimers
in the presence of SDS (Figures 1A, 3A) and monomers
in the presence of 8 M urea (Figures 1B, 3B). Thus we
establish that the dimeric character of AKAP12 and
these two large AKAP fragments reflects neither the
presence/absence of tags nor whether the proteins are
exogenously expressed in E. coli or endogenously in
mammalian cells, i.e., native AKAP12 oligomerizes.
Since AKAP12 mediates recycling and resensitization
of beta-adrenergic receptors [4,5,22-26], which mediate
elevation of intracellular cyclic AMP, we sought to inter-
rogate the effects of modulating cyclic AMP signaling
pathway on the oligomerization of AKAP12 (Figure 4).
Stimulation of cyclic AMP accumulation in HEK293
cells by stimulation of the cells with beta-adrenergic
agonist, isoproterenol, for 5 or 30 min had little effect
on the mobility of AKAP12 on SDS-PAGE, ~500 kDa-
Mr (Figure 4A). To test this possibility further, we
examined the effect of mutating the three sites of pro-
tein kinase A-catalyzed phosphorylation of AKAP12 on
the ability of the AKAP12 to form oligomers [22].
AKAP12 mutated by alanine substitution of protein
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Figure 3 Oligomerization of AKAP12 (and either C-terminal or N-terminal fragments) expressed in mammalian HEK293 cells.H u m a n
embryonic kidney (HEK) 293 cells were transfected with an empty expression vector or one harboring either full-length AKAP12, AKAP12 N-
terminal (1-938) or C-terminal (840-1782) regions. Whole-cell lysates of cells expressing either AKAP12 or one of the fragments were subjected to
SDS-PAGE in the absence (A) or presence of 8 M urea (B). The resolved proteins were transferred to PVDF membrane and subjected to
immunoblotting, stained for AKAP12 or the HA-tag. The results displayed are representative of at least three separate experiments performed on
as many separate cell cultures.
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Figure 4 Oligomerization of AKAP12 in mammalian cells: elevation of intracellular cyclic AMP as well as inhibition of protein kinase A,
MEK1/2, cyclic AMP phosphodiesterase 4, or expression of either N- or C-terminal fragments do not block AKAP oligomerization. (A)
HEK293 cells were transfected with an expression vector harboring either HA-tagged full-length AKAP12 (HA-AKAP12) or an HA-tagged AKAP12
in which alanine substitution of protein kinase A phosphorylation sites (S627A, S696-698A, S772A) has been performed (AKAP12M3). Cells were
treated with the beta-adrenergic agonist isoproterenol (10 μM) for 0, 5, or 30 min prior to harvesting the cells for lysis. Whole-cell lysates of
transfected cells expressing either AKAP12 or AKAP12M3 were subjected to SDS-PAGE in the absence of 8 M urea. (B) HEK293 cells were either
untreated or incubated with a chemical inhibitor for protein kinase A (KT5720, 1 μM), MEK1/2 (PD98059, 20 μM), or cyclic AMP
phosphodiesterase 4 (Rolipram, 10 μM) for 45 min prior to cell lysis and subsequent analysis by SDS-PAGE. (C) HEK293 cells were either
untransfected or transfected with an expression vector harboring the AKAP12 N-terminal (1-938) fragment or the C-terminal (840-1782) fragment.
Whole-cell lysates of cells expressing either AKAP12 or one of the fragments subjected to SDS-PAGE in the absence of 8 M urea. The resolved
proteins were transferred to PVDF membrane, subjected to immunoblotting, and made visible by staining with anti-HA or anti-AKAP12
antibodies. Beta-catenin was employed as a loading control for each lane, also identified by immunoblotting, stained with anti-beta-catenin
antibodies. The results displayed are representative of at least three separate experiments performed on as many separate cell cultures.
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Page 5 of 12kinase A phosphorylation sites (Ser627Ala, Ser696-
698Ala, Ser772Ala, labeled “AKAP12M3”) was expressed
in HEK293 cells, the cells treated without or with iso-
proterenol, and the Mr of AKAP12 established by SDS-
PAGE (Figure 4A). AKAP12M3 displayed the same Mr
(~500 kDa) as native AKAP12, i.e., no change in dimer
formation in response to stimulation of the cells with
isoproterenol. Cells were then challenged with inhibitors
to protein kinase A (KT5720), but also to cyclic AMP
phosphodiesterase 4 (PDE4, Rolipram), and to MEK1/2
(PD98059). The first two inhibitors test cyclic AMP sig-
naling by blocking protein kinase A and PDE4, respec-
tively, The third inhibits MEK1/2, the enzyme through
which the mitogen-activated kinase cascade (i.e., Erk1/2
activation) can be stimulated by beta-adrenergic activa-
tion, an AKAP-sensitive response (Figure 4B). Treating
the cells with any one of these specific enzyme inhibi-
tors did not noticeably alter AKAP12 oligomerization, i.
e., the Mr (~500 kDa) of AKAP12 on SDS-PAGE was
unaffected. Finally, we tested if the overexpression of
either the N-terminal (1-938) or the C-terminal (840-
1782) fragments in HEK293 cells would affect the for-
mation of the SDS-resistant dimers of full-length endo-
genous AKAP12 (Figure 4C). The presence of neither
fragment influenced the formation of the SDS-resistant
dimers (Mr ~500 kDa) of AKAP12. Both the N-terminal
and C-terminal fragments of AKAP12 expressed well in
the HEK293 cells, although the expression of the later
was more robust (Figure 4C).
Oligomerization of AKAP5
We sought to examine if the oligomeric behavior
observed for AKAP12 would be observed in a second,
much smaller, AKAP that docks to GPCRs, the AKAP5
(a.k.a., AKAP79; MW = 47.1 kDa versus 191.5 kDa for
AKAP12, based upon primary sequence). His-tagged
human AKAP5 was expressed in E. coli, purified by affi-
nity chromatography, and subjected to to SDS-PAGE in
the absence or presence of 8 M urea (Figure 5). In the
presence of either denaturant, AKAP5 behaves as a
monomer, although often as a doublet with Mr ~75 kDa
(Figure 5A, B). The microheterogenity of AKAP5
reflects, perhaps, differences in some post-translational
modifications, particularly protein phosphorylation. The
results of the protein staining were tested by immuno-
blotting of the AKAP with anti-AKAP5 antibody (Figure
5C, D). The immunoblotting and protein staining data
for AKAP5 mobility on gels are in good agreement. For-
mation of SDS-resistant AKAP5 oligomers, as we had
observed for AKAP12, was not observed.
We sought to explore further the possible existence of
AKAP5 dimers using somewhat less harsh conditions.
HA-tagged AKAP5 was expressed transiently in
HEK293 clones stably expressing GFP-tagged AKAP5
also. Pull-downs of HA-tagged AKAP5 were subjected
to SDS-PAGE and immunoblotting (Figure 6A). In
lysates of cells expressing two forms of exogenous
AKAP5 (HA-tagged and GFP-tagged AKAP5), pull-
downs of HA-tagged AKAP5 revealed the presence of
the GFP-tagged AKAP (Figure 6A). This observation
clearly suggests that AKAP5, like AKAP12, oligomerizes.
The possibility of dimerization/oligomerization of
AKAP5 was interrogated also by in vitro analysis of
AKAP5-AKAP5 binding making use of c-Myc tagged
AKAP5 (expressed and purified from yeast) in combina-
tion with His-tagged AKAP5 expressed and purified
from E. coli. A c-Myc-tagged AKAP5/anti-Myc antibody
that was coupled to protein G-agarose beads was pre-
pared. As a control, protein G-agarose beads were simi-
larly coupled with mouse IgG. The purified His-tagged
AKAP5 was incubated with both types of derivatized
protein G-agarose beads. Following incubation, the agar-
ose beads were collected, washed, and analyzed for His-
tagged AKAP5 bound to the c-Myc-tagged AKAP5 (Fig-
ure 6B). AKAP5 forms oligomers. The ability of His-
tagged AKAP5 to bind immobilized AKAP5 resolves the
k e yi s s u e .B ym a k i n gu s eo ft w od i f f e r e n ta p p r o a c h e s
with conditions less harsh that those tolerated by
AKAP12, we were able to establish that AKAP5 oligo-
merized. Pre-treating cells for 45 min with enzyme inhi-
bitors for MEK1/2 (PD98059) and PDE4 (Rolipram) had
no effect on the ability of HA-tagged AKAP5 to bind
GFP-tagged AKAP5 in pull-downs of the HA-tagged
version (Figure 6C), as shown by the presence of the
higher Mr GFP-tagged AKAP5 in the precipitate.
We employed again steric-exclusion chromatography on
a high-resolution, wide-bore matrix operated by an AKTA
FPLC to probe for AKAP5 oligomers (Figure 7). His-
tagged AKAP5 was expressed and purified from E. coli.
The purified AKAP5 was subjected to steric-exclusion
chromatography on Sephacryl-S400. The chromatograms
for AKAP5 and for A280 absorbance are displayed. Immu-
noblotting revealed a peak displaying a Mr of ~220 kDa
and a smaller second peak displaying a Mr. of ~44kDa, the
monomeric form of AKAP5 (Figure 7). Much like the
supermolecular complex of AKAP12, the size of the oligo-
mer of AKAP5 was consistent with that of an AKAP5 tet-
ramer. When the whole-cell lysates of E. coli expressing
His-tagged AKAP5 were subjected to the same steric-
exclusion chromatography, complexes of AKAP5 were
found to display higher Mr, ~740 kDa (data not shown).
Thus, the physical properties of purified AKAP5 include
the ability to form homo-oligomeric, supermolecular com-
plexes with Mr suggestive of tetrameric organization.
Discussion
The current work reports on new and important prop-
erties of AKAP. First, AKAP5 and AKAP12 are shown
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Page 6 of 12by several analytical methods to form homodimers. The
homodimers of AKAP12 are so avidly bound that only
in the presence of the strong chaotropic agent 8 M urea
are the dimers dissociated.
Oligomers of AKAP5, less avidly bound to each other,
were revealed through co-immunoprecipitation. AKAP5
is one-fourth the mass of AKAP12. Establishing the
structural basis for the oligomerization of each scaffold
will require additional studies. Second, AKAP5 and
AKAP12 appear to form higher-order oligomers. Based
upon steric-exclusion chromatography, the Mr of the
AKAP5 oligomers is ~220 kDa, whereas that of the
AKAP12 supermolecular complexes is ~840 kDa. The
presence of higher-order oligomers for two GPCR-asso-
ciating AKAPs suggests new and exciting possibilities
for AKAP biology. Higher order protein-protein interac-
tions, in which oligomers of AKAPs interact with other
signaling molecules e.g., including GPCRs, serine/threo-
nine protein kinases, tyrosine kinases, phosphoprotein
phosphatases, cyclic AMP phosphodiesterase(s), et al.,
opens new possibilities for a fuller understanding of
AKAP function. Not known is whether oligomerization
of AKAPs (i.e., AKAP5 and AKAP12) precludes or
includes the possibility of heterodimers/heterooligomers
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Figure 5 Oligomerization of AKAP5 expressed and purified from E. coli. His-tagged AKAP5 was expressed in E. coli. Affinity purified AKAP5
was resolved on either SDS-PAGE (A, C) or SDS-PAGE performed in the presence of 8 M urea (B, D). The gels were fixed and stained for protein
with Coomassie Brilliant Blue (A, B) or the resolved proteins transferred to PVDF membrane and subjected to immunoblotting (C, D).
Immunoblotting was performed using anti-AKAP5 antibody (C, D). The “◀” indicates the observed Mr on the gels and the “Δ” indicates the
predicted Mr, calculated from the MW (47 kDa).
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Figure 6 Oligomerization of AKAP5 in vivo and in vitro. (A) HEK293 cells stably expressing GFP-tagged AKAP5 were transiently transfected
with HA-tagged AKAP5. Cell lysates were subjected to pull-downs mediated by IgG (control) or anti-HA antibodies (IP-HA) and the pulldowns
subjected to SDS-PAGE, immunoblotting, and stained with anti-AKAP5 antibodies. Endogenous AKAP5 (expressed at <10% of that of
exogenously expressed, tagged-AKAP) display a Mr identical with the HA-tagged version under these conditions. (B) c-Myc-tagged AKAP5 fused
to amino acids 1-147 of the GAL4 DNA-binding domain (BD) was expressed in yeast. The c-Myc tagged AKAP5 was subjected to pull-down with
anti-c-Myc antibody or control IgG. The immune complexes then were incubated with purified His-tagged AKAP5. The association of His-tagged
AKAP5 with the c-Myc-tagged AKAP5 was detected by SDS-PAGE, immunoblotting, and staining of the blots with anti-AKAP5 antibodies. (C)
HEK293 cells stably expressing GFP-tagged AKAP5 were transiently co-transfected with an expression vector harboring HA-tagged AKAP5. The
cells were either untreated or incubated with a chemical inhibitor for either MEK1/2 (PD98059, 20 μM) or cyclic AMP phosphodiesterase 4
(Rolipram, 10 μM) for 45 min prior to cell lysis and analysis by SDS-PAGE. Pull-down of the HA-tagged AKAP5 was accomplished with anti-HA
antibodies. The immune precipitates were subjected to SDS-PAGE and immunoblotting. The resolved, transferred protein blots were stained with
anti-AKAP5 antibodies. The results displayed are representative of at least three separate experiments performed on as many separate cell
cultures.
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sence of higher-order supermolecular complexes invol-
ving more than one AKAP would constitute a new and
important dimension to AKAP biology.
The nature of the interaction that promotes the for-
mation of oligomers of AKAPs, remains to be estab-
lished. The primary sequences of AKAP5 and AKAP12
have been examined in detail with a least one startling
conclusion, i.e., the structures of these molecules are
predicted to be largely “natively-unordered.” FOLDin-
dex
© predicts intrinsic unfolding based upon the average
residue hydrophobicity and net charge in the protein
sequence [27,28]. Analysis using the FOLDIndex
© pre-
dicts human AKAP12 to be >90% natively unordered
primary sequence. By the same analysis, AKAP5 displays
>80% natively unordered sequence. This level of unor-
dered structure is remarkable when one considers the
number of proteins suspected to dock to AKAP12
[5,17,19]. Other members of the AKAP family, e.g.,
MAP2, also display major regions of natively unordered
sequence. AKAP1, in contrast, displays much more
ordered structure than AKAP12, AKAP5, or MAP2. By
comparison, the Dishevelled scaffold proteins (3 iso-
forms in vertebrates) that operates in Wnt signaling
display >85% ordered and little natively unordered
structure [29]. Dishevelleds displays DIX, PDZ, and DEP
domains and many docking partners also [30]. There-
fore, the “natively unordered” primary sequence of
AKAPs, like AKAP5 and AKAP12, must display docking
sites quite unlike those found in DIX, PDZ, and DEP
domains. The scaffolds are largely natively unordered,
but yet must contribute to the ability of the scaffold to
dock a myriad of signaling partners. Detailed studies of
AKAP12 reveal the presence of the Receptor-Binding
Domain for GPCRs [22], docking sites for protein kinase
C [23], and for PDE4 [6] in regions that are largely con-
sidered to be “natively unordered”. Reconciliation of
these seemingly paradoxical observations regarding the
unordered structure of AKAPs versus highly ordered
structure of scaffolds like Dishevelled family members
must awaited detailed structural analysis.
Conclusion
The current study demonstrates for the first time that
both AKAP5 and AKAP12 display the capacity to form
supermolecular homo-oligomeric structures that likely
influence the localization and function of these molecu-
lar scaffolds. Thus AKAP oligomerization adds a new
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Figure 7 Oligomerization of AKAP5 expressed and purified from E. coil: analysis of higher-order assembly by steric-exclusion
chromatography. His-tagged AKAP5 was expressed in E. coli. The AKAP5 was purified and then resolved by steric-exclusion chromatography
performed on an AKTA FPLC fitted with HiPrep Sephacryl-S400 (16/60) column. The presence of supermolecular oligomers of AKAP5 was
established by SDS-PAGE and immunoblotting of samples from the chromatography. The resolved, transferred proteins were stained with anti-
AKAP5 antibodies. Marker protein mobilities were employed to establish the Mr of AKAP5 by elution position (inset). The results displayed are
representative of two separate experiments performed on as many separate cell cultures.
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molecules operate in cell signaling.
Materials and methods
Reagents
Mouse anti-AKAP5, goat anti-mouse IgG-HRP, and goat
anti-rat IgG-HRP were purchased from Santa Cruz Bio-
technology (Santa Cruz, CA). Mouse anti-AKAP12
monoclonal antibody was from Abcam (Cambridge,
MA). Rat anti-HA antibody and HA-agarose beads were
products of Roche (Indianapolis, IN). Rabbit anti-b-cate-
nin antibody was from Sigma-Aldrich (St. Louis, MO).
Rolipram was from Cayman Chemical Company (Ann
Arbor, MI). PD98059 was a product of Millipore (Biller-
ica, MA).
Cell lines
T h eh u m a ne m b r y o n i ck i d n e yc e l ll i n eH E K 2 9 3
[6,16,18,31] was obtained from ATCC (Bethesda, MD)
and cultured in Dulbecco’s modified Eagle’sm e d i u m
(DMEM) containing 10% fetal bovine serum in a humi-
dified atmosphere containing 5% CO2 at 37°C. Conflu-
ent cells were treated with 10 μM isoproterenol (Iso) in
DMEM, for indicated times.
Plasmids and transfection
pcDNA3.1 vector harboring HA-tagged AKAP12, HA-
AKAP12M3 (S627A, S696-698A, S772A), HA-AKAP12
(1-938), and HA-AKAP12 (840-1782) were constructed
as described previously (23). pCMV-HA vector harbor-
ing AKAP5 was generated by PCR using specific primer
pairs 5’-GGAATTCGGATGGAAACCACAATTTCA-
GAAATTC-3’ and 5’-CCGCTCGAGTCACTGTAGAA-
GATTGTTTATTTTATTATC-3’.T h eP C Rp r o d u c t s
were subcloned into pCMV-HA between EcoRI and
Xho I sites. To generate His-tagged AKAP12(840-1782),
AKAP12(1-840) and AKAP5, the following primer pairs
were employed 5’-GGAATTCGATGGGCGCCGG-
GAGCTCCAC-3’ and 5’-CCGCTCGAGGTCATCT-
TCGTTGGCCCCTG-3’,5 ’-CGCGGATCCGGACTCT-
GATGTCCCGGCCGTGGTC-3’ and 5’-CCGCTCGA-
GAGATTCTGTAAGTTCTGACTTTGC-3’;5 ’-CGCG-
GATCCGATGGAAACCACAATTTCAGAAATTC-3’
and 5’-CCGCTCGAGCTGTAGAAGATTGTTTATTT-
TATTATCATC-3’ for PCR. The PCR products were
inserted into pET28b(+) (Novagen, Merck KGaA, Darm-
stadt, Germany) vector. pGBKT7 vector (expresses pro-
teins fused to amino acids 1-147 of the GAL4 DNA
binding domain (BD), c-Myc tag) harboring AKAP5 was
generated by PCR using primer pair 5’-GGAATTCATG-
GAAACCACAATTTCAGAAATTCATG-3’ and 5’-
TGACGCGTCGACTCACTGTAGAAGATTGTTTA-
TTTTATTATC-3’. The PCR product was subcloned
into pGBK-T7 vector between EcoR I and Sal I sites.
HEK293 cells were transfected with plasmid DNA using
ExpressFect (Denville Scientific, Metuchen, NJ), accord-
ing to the manufacturer’s instructions.
Purification of His-tagged AKAP5 and AKAP12
His-tagged AKAP5, AKAP12 (840-1782) and AKAP12
( 1 - 8 4 0 )e x p r e s s e di nE. coli were purified by using Ni-
NTA matrix (Qiagen, Valencia, CA), according to the
manufacturer’s protocol. His-tagged AKAP12 was puri-
fied by using Superose 12 column (12/29.5, GE Health-
care) pre-equilibrated with 20 mM Tris, 0.2 M NaCl
and 10% glycerol. Fractions containing AKAP12 were
collected.
In vitro analysis of AKAP5 dimerization
c-Myc-tagged AKAP5 fused to amino acids 1-147 of the
GAL4 DNA-binding domain (BD) was expressed in
yeast and pulled down from yeast lysates with anti-c-
Myc antibody. The c-Myc-tagged AKAP5/antibody com-
plex was absorbed to protein G-agarose beads. Protein
G-agarose beads similarly treated with mouse IgG
served as a control for this step. His-tagged AKAP5 was
expressed and purified from E. coli, as above. The puri-
fied His-tagged AKAP5 was incubated at 25°C for 1 h in
PBS containing 1% Triton X-100 and 1 mg/ml BSA in
combination with protein G-agarose beads to which
either c-Myc-tagged AKAP5 or control IgG were bound.
At the end of the incubation, the protein G-agarose
beads were collected and washed in PBS containing 1%
Triton X-100 three times; the beads then were collected
and heated with 30 μl Laemmli buffer at 95°C for 5
min. The supernatant was subjected to SDS-PAGE.
AKAP5 was detected by immunoblotting of the resolved
proteins using anti-AKAP5 antibody.
Steric-exclusion chromatography of AKAP supermolecular
complexes
Purified His-tagged AKAP5 or AKAP12 was applied to
the Sephacryl-S400 gel filtration column (HiPrep Sepha-
cryl S-400 High resolution 16/60, GE healthcare) mak-
ing use of a fast-performance liquid chromatography
system AKTA (GE Healthcare), pre-equilibrated with
PBS supplemented with 0.01% NaN3.S a m p l e( 1 . 0m l )
fractions were collected. Each fraction was analyzed by
SDS-PAGE and immunoblotting. Protein was detected
in the flow-cell by measuring absorbance at A280.
Immunoprecipitation and immunoblotting
Cells were harvested in a lysis buffer containing 20 mM
T r i s - H C l ,p H7 . 4 ,1 %N o n i d e tP - 4 0 ,2m Ms o d i u m
orthovanadate, 150 mM NaCl, 5 mM EDTA, 50 mM
NaF, 40 mM sodium pyrophosphate, 50 mM KH2PO4,
10 mM sodium molybdate, and a cocktail of protease
inhibitors (Complete Protease Inhibitor Cocktail tablet,
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Page 10 of 12Roche, Nutley, NJ). After centrifugation at 10,000 × g
for 15 min, the protein concentration of the supernatant
was determined using the Bradford reagent. One mg of
protein was incubated with specific primary antibody for
4 h at 4°C, then 20 μl of protein A/G agarose was added
and the mixture was incubated for 2 h on a rolling
mixer. Immune complexes were collected and washed
three times with PBS containing 1% Triton X-100, and
thereafter boiled for 5 min at 95°C in 30 μl of Laemmli
buffer. The supernatant was subjected to SDS-PAGE
and the resolved proteins were transferred to a PVDF
membrane. The blots were probed with specific antibo-
dies against target proteins. The immune complexes on
the blots were made visible by staining with a horserad-
ish peroxidase-conjugated secondary antibody in combi-
nation with the chemiluminescence reagent, followed by
a brief autoradiography using autoradiography film
(WorldWide Medical products Inc, Hamilton, NJ).
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